SCIProgramme

Design, synthesis, and study of new biologically active compounds and their preclinical and clinical development as potential anticancer pharmaceuticals. Development of biologically accessible formulations, drug systems, and therapeutic methods aimed at the treatment of cancer and leukaemias. These are the core goals of Research Programme 2 as presented by the programme’s leaders Michal Hocek and Marián Hajdúch.

The main goal of this research programme of the NICR is to discover the molecular mechanisms of cancers and to identify prognostic, stratification, and therapeutic targets using the methods of molecular genetics, multiomics, imaging methods, and advanced techniques of cell biology including CRISPR/Cas-9 gene editing. These are, in brief, the main targets of another of NICR’s research programmes and Jan Trka, its main leader, is presenting them jointly with Aleksi Šedo.

The three pillars of a NICR research programme focused on translational oncology presented by Pavel Klener jointly with the programme’s main leader, Ludmila Boublíková, are: First, a research of primary tumour cells, which – if we know the clinical parameters – can help us discover the genetic changes responsible for therapy resistance or cancer relapse.